252 related articles for article (PubMed ID: 16391154)
1. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling.
Dumitrascu R; Weissmann N; Ghofrani HA; Dony E; Beuerlein K; Schmidt H; Stasch JP; Gnoth MJ; Seeger W; Grimminger F; Schermuly RT
Circulation; 2006 Jan; 113(2):286-95. PubMed ID: 16391154
[TBL] [Abstract][Full Text] [Related]
2. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats.
Deruelle P; Balasubramaniam V; Kunig AM; Seedorf GJ; Markham NE; Abman SH
Biol Neonate; 2006; 90(2):135-44. PubMed ID: 16582538
[TBL] [Abstract][Full Text] [Related]
3. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
Schermuly RT; Stasch JP; Pullamsetti SS; Middendorff R; Müller D; Schlüter KD; Dingendorf A; Hackemack S; Kolosionek E; Kaulen C; Dumitrascu R; Weissmann N; Mittendorf J; Klepetko W; Seeger W; Ghofrani HA; Grimminger F
Eur Respir J; 2008 Oct; 32(4):881-91. PubMed ID: 18550612
[TBL] [Abstract][Full Text] [Related]
4. The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice.
Weissmann N; Hackemack S; Dahal BK; Pullamsetti SS; Savai R; Mittal M; Fuchs B; Medebach T; Dumitrascu R; Eickels Mv; Ghofrani HA; Seeger W; Grimminger F; Schermuly RT
Am J Physiol Lung Cell Mol Physiol; 2009 Oct; 297(4):L658-65. PubMed ID: 19617308
[TBL] [Abstract][Full Text] [Related]
5. Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3.
Steudel W; Scherrer-Crosbie M; Bloch KD; Weimann J; Huang PL; Jones RC; Picard MH; Zapol WM
J Clin Invest; 1998 Jun; 101(11):2468-77. PubMed ID: 9616218
[TBL] [Abstract][Full Text] [Related]
6. Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia.
Vermeersch P; Buys E; Pokreisz P; Marsboom G; Ichinose F; Sips P; Pellens M; Gillijns H; Swinnen M; Graveline A; Collen D; Dewerchin M; Brouckaert P; Bloch KD; Janssens S
Circulation; 2007 Aug; 116(8):936-43. PubMed ID: 17679618
[TBL] [Abstract][Full Text] [Related]
7. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.
Lang M; Kojonazarov B; Tian X; Kalymbetov A; Weissmann N; Grimminger F; Kretschmer A; Stasch JP; Seeger W; Ghofrani HA; Schermuly RT
PLoS One; 2012; 7(8):e43433. PubMed ID: 22912874
[TBL] [Abstract][Full Text] [Related]
8. Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats.
Masuyama H; Tsuruda T; Kato J; Imamura T; Asada Y; Stasch JP; Kitamura K; Eto T
Hypertension; 2006 Nov; 48(5):972-8. PubMed ID: 16982964
[TBL] [Abstract][Full Text] [Related]
9. Impaired iNOS-sGC-cGMP signalling contributes to chronic hypoxic and hypercapnic pulmonary hypertension in rat.
Xia XD; Xu ZJ; Hu XG; Wu CY; Dai YR; Yang L
Cell Biochem Funct; 2012 Jun; 30(4):279-85. PubMed ID: 22290599
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
11. BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats.
Thorsen LB; Eskildsen-Helmond Y; Zibrandtsen H; Stasch JP; Simonsen U; Laursen BE
Eur J Pharmacol; 2010 Nov; 647(1-3):147-54. PubMed ID: 20828552
[TBL] [Abstract][Full Text] [Related]
12. Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.
Potoka KP; Wood KC; Baust JJ; Bueno M; Hahn SA; Vanderpool RR; Bachman T; Mallampalli GM; Osei-Hwedieh DO; Schrott V; Sun B; Bullock GC; Becker-Pelster EM; Wittwer M; Stampfuss J; Mathar I; Stasch JP; Truebel H; Sandner P; Mora AL; Straub AC; Gladwin MT
Am J Respir Cell Mol Biol; 2018 May; 58(5):636-647. PubMed ID: 29268036
[TBL] [Abstract][Full Text] [Related]
13. Soluble guanylate cyclase stimulator, trans-4-methoxy-β-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats.
Gonzaga-Costa K; Vasconcelos-Silva AA; Rodrigues-Silva MJ; Rebouça CDSM; Duarte GP; Borges RS; Magalhães PJC; Lahlou S
Eur J Pharmacol; 2021 Apr; 897():173948. PubMed ID: 33609564
[TBL] [Abstract][Full Text] [Related]
14. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation.
Evgenov OV; Kohane DS; Bloch KD; Stasch JP; Volpato GP; Bellas E; Evgenov NV; Buys ES; Gnoth MJ; Graveline AR; Liu R; Hess DR; Langer R; Zapol WM
Am J Respir Crit Care Med; 2007 Dec; 176(11):1138-45. PubMed ID: 17872487
[TBL] [Abstract][Full Text] [Related]
15. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of nitric oxide-sensitive soluble guanylate cyclase in monocrotaline-induced pulmonary hypertensive rats.
Tawa M; Furukawa T; Tongu H; Sugihara M; Taguwa S; Yamanaka M; Yano Y; Matsumori H; Kitada R; Sawano T; Tanaka R; Ohkita M; Matsumura Y
Life Sci; 2018 Jun; 203():203-209. PubMed ID: 29705351
[TBL] [Abstract][Full Text] [Related]
17. YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice.
Huh JW; Kim SY; Lee JH; Lee YS
Pulm Pharmacol Ther; 2011 Dec; 24(6):638-46. PubMed ID: 21963997
[TBL] [Abstract][Full Text] [Related]
18. Analysis of responses to the Rho-kinase inhibitor Y-27632 in the pulmonary and systemic vascular bed of the rat.
Casey DB; Badejo AM; Dhaliwal JS; Sikora JL; Fokin A; Golwala NH; Greco AJ; Murthy SN; Nossaman BD; Hyman AL; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2010 Jul; 299(1):H184-92. PubMed ID: 20435851
[TBL] [Abstract][Full Text] [Related]
19. Effects of Sevoflurane on Hemodynamics and Inducible Nitric Oxide Synthase/Soluble Guanylate Cyclase Signaling Pathway in a Rat Model of Pulmonary Arterial Hypertension.
Qin G; Luo H; Yin X; Wang L; Zhang J; Cao Y; Zhang Z; Ye Z; Wang E
Anesth Analg; 2017 Jul; 125(1):184-189. PubMed ID: 28301419
[TBL] [Abstract][Full Text] [Related]
20. Carbon monoxide reverses established pulmonary hypertension.
Zuckerbraun BS; Chin BY; Wegiel B; Billiar TR; Czsimadia E; Rao J; Shimoda L; Ifedigbo E; Kanno S; Otterbein LE
J Exp Med; 2006 Sep; 203(9):2109-19. PubMed ID: 16908624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
